Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases)
Author:
Affiliation:
1. Dermatology Department Polyclinique Courlancy Reims France
2. GEM Resoverneuil
3. Dermatology Department Military Hospital Begin Saint‐Mandé France
4. Dermatology and Clinical Immunology Unit Antony Hospital Antony France
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16605
Reference6 articles.
1. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
2. The anti‐inflammatory potency of biologics targeting tumour necrosis factor‐α, interleukin (IL)‐17A,IL‐12/23 andCD20 in hidradenitis suppurativa: anex vivostudy
3. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa
4. Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study
5. Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Cross-Sectional Study of 3,207 Patients
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives;Annals of Medicine & Surgery;2024-07-01
2. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study;Dermatology and Therapy;2024-06-19
3. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa;Expert Opinion on Biological Therapy;2024-04-02
4. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials;British Journal of Dermatology;2024-03-12
5. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3